What is Viome?
Viome operates at the intersection of biotechnology and consumer health, specializing in at-home microbiome intelligence testing. By leveraging advanced RNA sequencing technology and sophisticated machine learning algorithms, the company provides users with granular insights into their gut, oral, and systemic health. This data-driven approach allows Viome to offer highly tailored dietary recommendations and precision supplements, effectively positioning itself as a leader in the burgeoning longevity market. The company serves a diverse demographic, ranging from data-conscious health enthusiasts to individuals managing chronic health symptoms, thereby establishing a robust market presence in the personalized medicine landscape.
How much funding has Viome raised?
Viome has raised a total of $163M across 5 funding rounds:
Series A
$15M
Series B
$5.5M
Debt
$2M
Other Financing Round
$54M
Series C
$86.5M
Series A (2017): $15M with participation from Khosla Ventures and BOLD CAPITAL PARTNERS
Series B (2018): $5.5M led by Khosla Ventures and Physician Partners
Debt (2020): $2M supported by PPP
Other Financing Round (2021): $54M featuring Glico, Khosla Ventures, WestRiver Group, BOLD Capital Group, and Physician Partners
Series C (2023): $86.5M backed by BOLD Capital Group, Khosla Ventures, and WRG Ventures
Key Investors in Viome
Khosla Ventures
A prominent venture capital firm founded by Vinod Khosla, focusing on breakthrough technologies across sectors including health, AI, and sustainable energy.
BOLD Capital Group
A specialized investment and advisory firm that provides strategic capital and operational support to early-stage technology platforms in healthcare and beyond.
WestRiver Group
A thematically-driven investment platform dedicated to supporting purpose-driven enterprises that leverage innovation to enhance societal well-being.
What's next for Viome?
With the recent influx of capital, Viome is well-positioned to deepen its research and development efforts, particularly in the identification of biomarkers associated with chronic disease. The strategic focus will likely shift toward expanding its clinical validation studies and enhancing its AI-driven recommendation engine to improve user outcomes. As the company matures, it is expected to leverage its extensive proprietary dataset to forge deeper partnerships within the healthcare ecosystem, potentially integrating its diagnostic capabilities into broader clinical workflows. This phase of growth will be critical in transitioning Viome from a direct-to-consumer health platform to a foundational player in the future of preventative, data-centric healthcare.
See full Viome company page
